PT-141* · Bremelanotide*

Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.

PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist derived from the alpha-MSH family. Research has focused primarily on sexual desire and arousal, with clinical studies demonstrating effects on sexual desire and distress associated with hypoactive sexual desire disorder.

Research Benefits

Sexual desire research involving melanocortin signaling and central nervous system pathways

Arousal research involving neural mechanisms associated with sexual response

HSDD research with demonstrated improvements in sexual desire in clinical trials

Melanocortin receptor research involving MC4R and related signaling pathways

Female sexual-function research supported by extensive clinical investigation

Identified Risks & Side Effects

Nausea is the most frequently reported adverse effect in clinical studies

Flushing and headache are also commonly reported

Temporary increases in blood pressure can occur following administration

Skin pigmentation changes may occur with melanocortin activity

Long-term use requires medical oversight because safety and effectiveness depend on the specific clinical indication

Route: Subcutaneous, in clinical formulations | Frequency: As needed in approved clinical use | FDA Status: FDA-approved for a specific medical indication

Researcher Note

PT-141 is one of the more extensively studied melanocortin peptides, with clinical trials involving more than 1,000 women in the pivotal phase 3 program. The RECONNECT trials demonstrated statistically significant improvements in sexual desire and reductions in distress associated with low sexual desire. Bremelanotide has also undergone longer-term clinical evaluation, providing substantially more human safety data than many experimental melanocortin peptides. citeturn0search0turn0search2

Disclaimer

FDA Status: FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; this approval does not apply to other uses
Research Classification: Research use only
Compound Type: Synthetic cyclic heptapeptide / melanocortin receptor agonist

All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.